December 11, 2022

Important Deadline Approaching for Voyager Digital Holdings Investors: Seek Counsel Now, Advises Trusted National Trial Counsel Rosen in Securities Class Action for VGX Losses

marketinsights03 mins

The Impact of Voyager Digital Holdings Investor Losses Introduction Recently, Rosen Law Firm has issued a reminder to purchasers of Voyager Earn Accounts and VGX tokens about potential losses incurred between January 1, 2020 and November 9, 2022. This news has caused a stir among investors and raised questions about the security and reliability of…

Read More

Unleashing the Power of Science: Senti Bio’s Exciting Preclinical Findings at the ASH Annual Meeting and Investor Event!

newscaster05 mins

Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting… Exciting Advances in Cell Therapy Have you heard the latest buzz from the ASH Annual Meeting? Senti Bio presented groundbreaking preclinical data on their innovative off-the-shelf CAR-NK cell therapy candidate, SENTI-202. This therapy is engineered with a logic-gated…

Read More

Agios Unveils Latest Pyrukynd Mitapivat Findings: Promising Long-Term Safety and Hemoglobin Improvement in Non-Transfusion Dependent Patients

marketinsights03 mins

Agios Pharmaceuticals Presents Updated PYRUKYND® Data Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Agios Pharmaceuticals, Inc. is currently conducting Phase 3 ENERGIZE and ENERGIZE-T studies to evaluate the effectiveness of PYRUKYND® in adults with non-transfusion-dependent and transfusion-dependent α- or β-Thalassemia, respectively. This innovative drug has shown promise in improving outcomes for patients with these…

Read More